ArticleChronic respiratory disease
Global, regional and national trends in burden of chronic obstructive pulmonary disease from 2000 to 2021 and the prediction for 2030.
Article in Chronic respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research status and development trends of chronic obstructive pulmonary disease and gut microbiota: a comprehensive analysis based on bibliometrics and knowledge visualization.Frontiers in microbiology · 2026Pooled it
- Effectiveness of Adding Thoracic Manual Therapy to Conventional Pulmonary Rehabilitation for Improving Pulmonary Function and Chest Expansion in Adults with Restrictive Ventilatory Impairment: A Randomized Controlled Trial.Life (Basel, Switzerland) · 2026Article
- Article
- Multi‑feature Prediction Model for Coronary Heart Disease Comorbidity in Middle‑aged and Older Adults with COPD Based on Machine Learning and SHAP.International journal of chronic obstructive pulmonary disease · 2026Article
- Global, regional and national trends in burden of chronic obstructive pulmonary disease from 2000 to 2021 and the prediction for 2030.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
AimsTo estimate the global burden of chronic obstructive pulmonary disease (COPD) by age, gender and socioeconomic status from 2000 to 2021, and make a prediction until 2030.MethodsData were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. The burden of COPD, referred to absolute numbers of COPD case and age-standardized rates (ASRs) per 100,000 individuals per year. The temporal trends from 2000 to 2021 were examined using Joinpoint models. Bayesian age-period-cohort models were introduced to project the burden until 2030. Finally, a decomposition analysis was conducted to reveal the contributions of aging, population growth and epidemiological changes to trends in COPD burden.ResultsThe crude numbers of incident cases, prevalent cases, deaths, and disability-adjusted life years (DALYs) for COPD remained increasing from 2000 to 2021, and until 2030, worldwide. ASRs of incidence, prevalence, deaths, and DALYs were in decreasing trends, and would continue to decline until 2030. Additionally, in 2021, the ASR of COPD burden was higher in males than females, while the age-specific rate increased with age. The disease burden varied across different regions, with a high burden in low development-level regions. The increasing burden of COPD was primarily driven by rapid aging and population growth.ConclusionsThe global ASRs of COPD burden would remain declining, but the crude burden would continue to increase until 2030. This study has public health implications for population-based interventions against COPD with consideration of residents' age, gender and residing area as well as economic status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.